In the dynamic landscape of pharmaceutical manufacturing, the availability of high-quality intermediates is paramount. NINGBO INNO PHARMCHEM CO.,LTD. is proud to present (S)-1-(3-(2-(7-Chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol, identified by its Chemical Abstracts Service (CAS) No. 142569-70-8. This sophisticated chemical compound serves as a critical pharmaceutical intermediate, playing a pivotal role in the synthesis of vital active pharmaceutical ingredients (APIs).

Pharmaceutical intermediates are the foundational building blocks in the intricate multi-step process of drug synthesis. Unlike active pharmaceutical ingredients (APIs), which are the core therapeutic components of a drug, intermediates are transitional compounds that undergo further chemical transformations and purifications before becoming the final API. They are essential for breaking down complex synthesis into manageable stages, ensuring efficient and controlled production. The global pharmaceutical intermediates market is experiencing robust growth, driven by increasing demand for generic drugs and the rising prevalence of chronic diseases, highlighting the indispensable role these compounds play in the healthcare industry.

The significance of a high-quality intermediate like (S)-1-(3-(2-(7-Chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol cannot be overstated. Its molecular formula, C29H28ClNO2, and molecular weight of 457.99 indicate a complex structure engineered for specific chemical reactions. With a minimum purity of 97% and an appearance ranging from off-white to yellow foam, this intermediate meets stringent quality requirements. Its primary application as a pharmaceutical raw intermediate, specifically noted as a Montelukast intermediate or Monluster sodium intermediate, underscores its importance in producing anti-asthma and anti-allergy medications. Any compromise in the purity or consistency of such an intermediate could directly impact the efficacy and safety of the final drug product, making stringent quality control measures absolutely essential.

NINGBO INNO PHARMCHEM CO.,LTD. adheres to rigorous quality control protocols throughout the manufacturing process, from sourcing premium raw materials to implementing advanced synthesis techniques. Our commitment ensures that every batch of (S)-1-(3-(2-(7-Chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol (CAS No. 142569-70-8) consistently meets the highest industry standards. This dedication is crucial for maintaining regulatory compliance and facilitating the smooth approval and market release of pharmaceutical products globally. The intricate synthesis of such compounds requires deep expertise in organic chemistry and state-of-the-art facilities, capabilities that NINGBO INNO PHARMCHEM CO.,LTD. possesses.

As the pharmaceutical industry continues to expand, the demand for reliable and high-quality pharmaceutical intermediates remains strong. Manufacturers seeking a trustworthy supplier for (S)-1-(3-(2-(7-Chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol (CAS No. 142569-70-8) will find NINGBO INNO PHARMCHEM CO.,LTD. to be a dependable partner. We focus on providing competitive price offerings and flexible purchase options to meet diverse client needs. To buy this essential chemical, or to inquire about bulk supply, please reach out to our sales team. We are committed to fostering long-term partnerships by providing exceptional product quality and consistent supply, ensuring that our clients can effectively accelerate their drug development and production timelines.